The company is focused on discovering and developing novel immunotherapies for orphan diseases, with a particular emphasis on cancer treatments. Cytovac is a leader in the field of individualized cell-based therapies for solid tumors and is using the ALECSAT platform to generate best-in-class therapeutics. By injecting activated cells from the immune system, Cytovac is developing treatments that use the body's own immune system to fight cancer. The company's goal is to address high unmet medical needs in cancer and other orphan diseases.